NHC vs. VRTX

Last updated Apr 1, 2026

Compare and contrast key facts about National HealthCare Corporation (NHC) and Vertex Pharmaceuticals Incorporated (VRTX).

Performance

NHC vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in National HealthCare Corporation (NHC) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

NHC vs. VRTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NHC National HealthCare Corporation	16.95%	30.34%	19.05%	60.84%	-9.42%	5.39%	-20.66%	13.02%	32.43%	-17.26%
VRTX Vertex Pharmaceuticals Incorporated	-1.50%	12.58%	-1.03%	40.90%	31.50%	-7.08%	7.94%	32.13%	10.58%	103.42%

Fundamentals

EPS NHC : $6.48 VRTX : $15.35
PE Ratio NHC : 24.66 VRTX : 29.09
PEG Ratio NHC : 0.54 VRTX : 2.42
PS Ratio NHC : 1.66 VRTX : 9.58
Total Revenue (TTM) NHC : $1.50B VRTX : $12.00B
Gross Profit (TTM) NHC : $578.46M VRTX : $10.35B
EBITDA (TTM) NHC : $188.85M VRTX : $4.74B

Returns By Period

In the year-to-date period, NHC achieves a 16.95% return, which is significantly higher than VRTX's -1.50% return. Over the past 10 years, NHC has underperformed VRTX with an annualized return of 12.95%, while VRTX has yielded a comparatively higher 18.89% annualized return.

NHC

• 1D: -1.27%
• 1M: -1.94%
• YTD: 16.95%
• 6M: 32.56%
• 1Y: 75.52%
• 3Y*: 43.60%
• 5Y*: 18.85%
• 10Y*: 12.95%

VRTX

• 1D: 0.76%
• 1M: -10.12%
• YTD: -1.50%
• 6M: 14.02%
• 1Y: -7.90%
• 3Y*: 12.33%
• 5Y*: 15.95%
• 10Y*: 18.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NHC vs. VRTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NHC

NHC Risk / Return Rank: 94
NHC Sharpe Ratio Rank: 95
NHC Sortino Ratio Rank: 94
NHC Omega Ratio Rank: 92
NHC Calmar Ratio Rank: 95
NHC Martin Ratio Rank: 95

VRTX

VRTX Risk / Return Rank: 31
VRTX Sharpe Ratio Rank: 32
VRTX Sortino Ratio Rank: 29
VRTX Omega Ratio Rank: 29
VRTX Calmar Ratio Rank: 32
VRTX Martin Ratio Rank: 31

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NHC vs. VRTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for National HealthCare Corporation (NHC) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NHC	VRTX	Difference
Sharpe ratio Return per unit of total volatility	2.65	-0.22	+2.87
Sortino ratio Return per unit of downside risk	3.44	-0.05	+3.49
Omega ratio Gain probability vs. loss probability	1.42	0.99	+0.43
Calmar ratio Return relative to maximum drawdown	5.81	-0.33	+6.14
Martin ratio Return relative to average drawdown	16.35	-0.65	+17.00
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NHC vs. VRTX - Sharpe Ratio Comparison

The current NHC Sharpe Ratio is 2.65, which is higher than the VRTX Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of NHC and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NHC	VRTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.65	-0.22	+2.87
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.71	0.56	+0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.47	0.57	-0.10
Sharpe Ratio (All Time) Calculated using the full available price history	0.24	0.26	-0.02

Correlation

The correlation between NHC and VRTX is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NHC vs. VRTX - Dividend Comparison

NHC's dividend yield for the trailing twelve months is around 1.60%, while VRTX has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NHC National HealthCare Corporation	1.60%	1.85%	2.25%	2.53%	3.80%	3.11%	3.13%	2.38%	2.52%	3.10%	2.31%	3.14%
VRTX Vertex Pharmaceuticals Incorporated	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

NHC vs. VRTX - Drawdown Comparison

The maximum NHC drawdown since its inception was -96.33%, roughly equal to the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for NHC and VRTX.

Drawdown Indicators

	NHC	VRTX	Difference
Max Drawdown Largest peak-to-trough decline	-96.33%	-91.77%	-4.56%
Max Drawdown (1Y) Largest decline over 1 year	-13.13%	-28.06%	+14.93%
Max Drawdown (5Y) Largest decline over 5 years	-33.40%	-29.07%	-4.33%
Max Drawdown (10Y) Largest decline over 10 years	-35.27%	-41.60%	+6.33%
Current Drawdown Current decline from peak	-7.23%	-13.59%	+6.36%
Average Drawdown Average peak-to-trough decline	-26.53%	-37.81%	+11.28%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.67%	14.33%	-9.66%

Volatility

NHC vs. VRTX - Volatility Comparison

The current volatility for National HealthCare Corporation (NHC) is 8.37%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 11.93%. This indicates that NHC experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NHC	VRTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.37%	11.93%	-3.56%
Volatility (6M) Calculated over the trailing 6-month period	20.47%	21.67%	-1.20%
Volatility (1Y) Calculated over the trailing 1-year period	28.65%	35.83%	-7.18%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.85%	28.77%	-1.92%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.60%	33.24%	-5.64%

Financials

NHC vs. VRTX - Profitability Comparison

The chart below illustrates the profitability comparison between National HealthCare Corporation and Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NHC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, National HealthCare Corporation reported a gross profit of 149.49M and revenue of 382.66M. Therefore, the gross margin over that period was 39.1%.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.72B and revenue of 3.19B. Therefore, the gross margin over that period was 85.4%.

NHC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, National HealthCare Corporation reported an operating income of 30.38M and revenue of 382.66M, resulting in an operating margin of 7.9%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.26B and revenue of 3.19B, resulting in an operating margin of 39.6%.

NHC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, National HealthCare Corporation reported a net income of 39.24M and revenue of 382.66M, resulting in a net margin of 10.3%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.19B and revenue of 3.19B, resulting in a net margin of 37.3%.